Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Klimawandel und Gesundheit: Was Sie in der Hausarztpraxis wissen müssen und tun können

Die Folgen des Klimwandels haben einen direkten Einfluss auf die Primärversorgung in Deutschland: Hitzeschutz insbesondere bei älteren Patienten, die Zunahme von Infektionen und die Verlängerung der Allergiesesaison spielen medizinisch eine bedeutsame Rolle. Aber auch in der Prävention und der Aufklärung der Patienten kommt den Hausärztinnen und -ärzten eine besondere Rolle zu. Direkt aus der Praxis berichtet im Live-Webinar am 13. Mai von 18 bis 19 Uhr unser Experte Dr. med. Robin Maitra.
Erweiterte Suche
Anmelden
nach oben
Current Hematologic Malignancy Reports
Erschienen in: Current Hematologic Malignancy Reports 2/2019

08.03.2019 | T-Cell and Other Lymphoproliferative Malignancies (J Zain, Section Editor)

Development and Significance of Mouse Models in Lymphoma Research

verfasst von: Jordan N. Noble, Anjali Mishra

Erschienen in: Current Hematologic Malignancy Reports | Ausgabe 2/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Animal models have played an indispensable role in interpreting cancer gene functions, pathogenesis of disease, and in the development of innovative therapeutic approaches targeting aberrant biological pathways in human cancers.

Recent Findings

These models have guided the therapeutic targeting of cancer-causing mutations and paved the way for assessing anti-cancer drug responses and the preclinical development of immunotherapies. The mammalian models of cancer utilize genetically edited or transplanted mice that develop fairly accurate disease histopathology. The mouse model also allows us to study the effect of tumor microenvironment in the development of lymphoma. The emergence of patient-derived xenografts provides a better opportunity for recapitulating primary lymphoma characteristics and researching personalized drug therapy.

Summary

In conclusion, the refinement and advancement of available mouse models in lymphoma significantly minimize the therapeutic translational failures in patients.
Literatur
1.
Marconato L, Gelain ME, Comazzi S. The dog as a possible animal model for human non-Hodgkin lymphoma: a review. Hematol Oncol. 2013;31(1):1–9.CrossRefPubMed
2.
Larsdotter S, Nostell K, von Euler H. Serum thymidine kinase activity in clinically healthy and diseased horses: a potential marker for lymphoma. Vet J. 2015;205(2):313–6.CrossRefPubMed
3.
4.
Perlman RL. Mouse models of human disease: an evolutionary perspective. Evol Med Public Health. 2016;2016(1):170–6.PubMedPubMedCentral
5.
6.
Sonoshita M, Cagan RL. Modeling human cancers in Drosophila. Curr Top Dev Biol. 2017;121:287–309.CrossRefPubMed
7.
8.
Kuppers R. New insights in the biology of Hodgkin lymphoma. Hematology Am Soc Hematol Educ Program. 2012;2012:328–34.PubMed
9.
Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(4):235–42.CrossRefPubMed
10.
Herman SEM, Montraveta A, Niemann CU, Mora-Jensen H, Gulrajani M, Krantz F, et al. The Bruton tyrosine kinase (BTK) inhibitor Acalabrutinib demonstrates potent on-target effects and efficacy in two mouse models of chronic lymphocytic leukemia. Clin Cancer Res. 2017;23(11):2831–41.CrossRefPubMed
11.
Dubovsky JA, Beckwith KA, Natarajan G, Woyach JA, Jaglowski S, Zhong Y, et al. Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. Blood. 2013;122(15):2539–49.CrossRefPubMedPubMedCentral
12.
Roberts ZJ, Better M, Bot A, Roberts MR, Ribas A. Axicabtagene ciloleucel, a first-in-class CAR T cell therapy for aggressive NHL. Leuk Lymphoma. 2018;59(8):1785–96.CrossRefPubMed
13.
Kochenderfer JN, Yu Z, Frasheri D, Restifo NP, Rosenberg SA. Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells. Blood. 2010;116(19):3875–86.CrossRefPubMedPubMedCentral
14.
Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene Ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377(26):2531–44.CrossRefPubMedPubMedCentral
15.
Patnaik A, Appleman LJ, Tolcher AW, Papadopoulos KP, Beeram M, Rasco DW, et al. First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas. Ann Oncol. 2016;27(10):1928–40.CrossRefPubMedPubMedCentral
16.
Rava M, D'Andrea A, Nicoli P, Gritti I, Donati G, Doni M, et al. Therapeutic synergy between tigecycline and venetoclax in a preclinical model of MYC/BCL2 double-hit B cell lymphoma. Sci Transl Med. 2018;10(426):eaan8723.CrossRefPubMed
17.
O'Steen S, Green DJ, Gopal AK, Orozco JJ, Kenoyer AL, Lin Y, et al. Venetoclax synergizes with radiotherapy for treatment of B-cell lymphomas. Cancer Res. 2017;77(14):3885–93.CrossRefPubMedPubMedCentral
18.
Pham LV, Huang S, Zhang H, Zhang J, Bell T, Zhou S, et al. Strategic therapeutic targeting to overcome Venetoclax resistance in aggressive B-cell lymphomas. Clin Cancer Res. 2018;24(16):3967–80.CrossRefPubMed
19.
Tam CS, Anderson MA, Pott C, Agarwal R, Handunnetti S, Hicks RJ, et al. Ibrutinib plus Venetoclax for the treatment of mantle-cell lymphoma. N Engl J Med. 2018;378(13):1211–23.CrossRefPubMed
20.
Paoluzzi L, Scotto L, Marchi E, Zain J, Seshan VE, O'Connor OA. Romidepsin and belinostat synergize the antineoplastic effect of bortezomib in mantle cell lymphoma. Clin Cancer Res. 2010;16(2):554–65.CrossRefPubMed
21.
O'Connor OA, Horwitz S, Masszi T, Van Hoof A, Brown P, Doorduijn J, et al. Belinostat in patients with relapsed or refractory peripheral T-cell lymphoma: results of the pivotal phase II BELIEF (CLN-19) study. J Clin Oncol. 2015;33(23):2492–9.CrossRefPubMedPubMedCentral
22.
Bhatt S, Ashlock BM, Natkunam Y, Sujoy V, Chapman JR, Ramos JC, et al. CD30 targeting with brentuximab vedotin: a novel therapeutic approach to primary effusion lymphoma. Blood. 2013;122(7):1233–42.CrossRefPubMedPubMedCentral
23.
Ju W, Zhang M, Wilson KM, Petrus MN, Bamford RN, Zhang X, et al. Augmented efficacy of brentuximab vedotin combined with ruxolitinib and/or Navitoclax in a murine model of human Hodgkin's lymphoma. Proc Natl Acad Sci U S A. 2016;113(6):1624–9.CrossRefPubMedPubMedCentral
24.
Connors JM, Jurczak W, Straus DJ, Ansell SM, Kim WS, Gallamini A, et al. Brentuximab Vedotin with chemotherapy for stage III or IV Hodgkin's lymphoma. N Engl J Med. 2018;378(4):331–44.CrossRefPubMed
25.
Fridman WH, Pages F, Sautes-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer. 2012;12(4):298–306.CrossRefPubMed
26.
Honeychurch J, Melis MH, Dovedi SJ, Mu L, Illidge TM. Immunogenic potential of irradiated lymphoma cells is enhanced by adjuvant immunotherapy and modulation of local macrophage populations. Leuk Lymphoma. 2013;54(9):2008–15.CrossRefPubMed
27.
Assaf N, Hasson T, Hoch-Marchaim H, Pe'er J, Gnessin H, Deckert-Schluter M, et al. An experimental model for infiltration of malignant lymphoma to the eye and brain. Virchows Arch. 1997;431(6):459–67.CrossRefPubMed
28.
Yan ZX, Wu LL, Xue K, Zhang QL, Guo Y, Romero M, et al. MicroRNA187 overexpression is related to tumor progression and determines sensitivity to bortezomib in peripheral T-cell lymphoma. Leukemia. 2014;28(4):880–7.CrossRefPubMed
29.
Turaj AH, Cox KL, Penfold CA, French RR, Mockridge CI, Willoughby JE, et al. Augmentation of CD134 (OX40)-dependent NK anti-tumour activity is dependent on antibody cross-linking. Sci Rep. 2018;8(1):2278.CrossRefPubMedPubMedCentral
30.
• Day CP, Merlino G, Van Dyke T. Preclinical mouse cancer models: a maze of opportunities and challenges. Cell. 2015;163(1):39–53. This article cites several pre-clinical mouse models and highlights experimental concerns.CrossRefPubMedPubMedCentral
31.
Sagiv-Barfi I, Kohrt HE, Burckhardt L, Czerwinski DK, Levy R. Ibrutinib enhances the antitumor immune response induced by intratumoral injection of a TLR9 ligand in mouse lymphoma. Blood. 2015;125(13):2079–86.CrossRefPubMedPubMedCentral
32.
Di Rosso ME, Sterle HA, Cremaschi GA, Genaro AM. Beneficial effect of fluoxetine and sertraline on chronic stress-induced tumor growth and cell dissemination in a mouse model of lymphoma: crucial role of antitumor immunity. Front Immunol. 2018;9:1341.CrossRefPubMedPubMedCentral
33.
Rafferty P, Egenolf D, Brosnan K, Makropoulos D, Jordan J, Meshaw K, et al. Immunotoxicologic effects of cyclosporine on tumor progression in models of squamous cell carcinoma and B-cell lymphoma in C3H mice. J Immunotoxicol. 2012;9(1):43–55.CrossRefPubMed
34.
Cheadle EJ, Sheard V, Rothwell DG, Bridgeman JS, Ashton G, Hanson V, et al. Differential role of Th1 and Th2 cytokines in autotoxicity driven by CD19-specific second-generation chimeric antigen receptor T cells in a mouse model. J Immunol. 2014;192(8):3654–65.CrossRefPubMed
35.
Dayde D, Ternant D, Ohresser M, Lerondel S, Pesnel S, Watier H, et al. Tumor burden influences exposure and response to rituximab: pharmacokinetic-pharmacodynamic modeling using a syngeneic bioluminescent murine model expressing human CD20. Blood. 2009;113(16):3765–72.CrossRefPubMed
36.
Cheadle EJ, Lipowska-Bhalla G, Dovedi SJ, Fagnano E, Klein C, Honeychurch J, et al. A TLR7 agonist enhances the antitumor efficacy of obinutuzumab in murine lymphoma models via NK cells and CD4 T cells. Leukemia. 2017;31(7):1611–21.CrossRefPubMedPubMedCentral
37.
Berge G, Eliassen LT, Camilio KA, Bartnes K, Sveinbjornsson B, Rekdal O. Therapeutic vaccination against a murine lymphoma by intratumoral injection of a cationic anticancer peptide. Cancer Immunol Immunother. 2010;59(8):1285–94.CrossRefPubMed
38.
Matsumoto T, Suetsugu A, Shibata Y, Nakamura N, Aoki H, Kunisada T, et al. A color-coded Imageable syngeneic mouse model of stromal-cell recruitment by metastatic lymphoma. Anticancer Res. 2015;35(9):4647–54.PubMed
39.
40.
Passineau MJ, Siegal GP, Everts M, Pereboev A, Jhala D, Wang M, et al. The natural history of a novel, systemic, disseminated model of syngeneic mouse B-cell lymphoma. Leuk Lymphoma. 2005;46(11):1627–38.CrossRefPubMed
41.
Talmadge JE, Singh RK, Fidler IJ, Raz A. Murine models to evaluate novel and conventional therapeutic strategies for cancer. Am J Pathol. 2007;170(3):793–804.CrossRefPubMedPubMedCentral
42.
Cho SY, Kang W, Han JY, Min S, Kang J, Lee A, et al. An integrative approach to precision Cancer medicine using patient-derived xenografts. Mol Cell. 2016;39(2):77–86.CrossRef
43.
Chapuy B, Cheng H, Watahiki A, Ducar MD, Tan Y, Chen L, et al. Diffuse large B-cell lymphoma patient-derived xenograft models capture the molecular and biological heterogeneity of the disease. Blood. 2016;127(18):2203–13.CrossRefPubMedPubMedCentral
44.
Ravi D, Bhalla S, Gartenhaus RB, Crombie J, Kandela I, Sharma J, et al. The novel organic arsenical darinaparsin induces MAPK-mediated and SHP1-dependent cell death in T-cell lymphoma and Hodgkin lymphoma cells and human xenograft models. Clin Cancer Res. 2014;20(23):6023–33.CrossRefPubMedPubMedCentral
45.
DiFranco KM, Johnson-Farley N, Bertino JR, Elson D, Vega BA, Belinka BA Jr, et al. LFA-1-targeting Leukotoxin (LtxA; Leukothera(R)) causes lymphoma tumor regression in a humanized mouse model and requires caspase-8 and Fas to kill malignant lymphocytes. Leuk Res. 2015;39(6):649–56.CrossRefPubMedPubMedCentral
46.
Chan-Penebre E, Kuplast KG, Majer CR, Boriack-Sjodin PA, Wigle TJ, Johnston LD, et al. A selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL models. Nat Chem Biol. 2015;11(6):432–7.CrossRefPubMed
47.
Tsukahara T, Ohmine K, Yamamoto C, Uchibori R, Ido H, Teruya T, et al. CD19 target-engineered T-cells accumulate at tumor lesions in human B-cell lymphoma xenograft mouse models. Biochem Biophys Res Commun. 2013;438(1):84–9.CrossRefPubMedPubMedCentral
48.
Hao Y, Chapuy B, Monti S, Sun HH, Rodig SJ, Shipp MA. Selective JAK2 inhibition specifically decreases Hodgkin lymphoma and mediastinal large B-cell lymphoma growth in vitro and in vivo. Clin Cancer Res. 2014;20(10):2674–83.CrossRefPubMedPubMedCentral
49.
George SK, Vishwamitra D, Manshouri R, Shi P, Amin HM. The ALK inhibitor ASP3026 eradicates NPM-ALK(+) T-cell anaplastic large-cell lymphoma in vitro and in a systemic xenograft lymphoma model. Oncotarget. 2014;5(14):5750–63.CrossRefPubMedPubMedCentral
50.
Goto H, Kudo E, Kariya R, Taura M, Katano H, Okada S. Targeting VEGF and interleukin-6 for controlling malignant effusion of primary effusion lymphoma. J Cancer Res Clin Oncol. 2015;141(3):465–74.CrossRefPubMed
51.
Gasperini P, Tosato G. Targeting the mammalian target of rapamycin to inhibit VEGF and cytokines for the treatment of primary effusion lymphoma. Leukemia. 2009;23(10):1867–74.CrossRefPubMedPubMedCentral
52.
Kopetz S, Lemos R, Powis G. The promise of patient-derived xenografts: the best laid plans of mice and men. Clin Cancer Res. 2012;18(19):5160–2.CrossRefPubMedPubMedCentral
53.
Shimada K, Shimada S, Sugimoto K, Nakatochi M, Suguro M, Hirakawa A, et al. Development and analysis of patient-derived xenograft mouse models in intravascular large B-cell lymphoma. Leukemia. 2016;30(7):1568–79.CrossRefPubMed
54.
Zhang L, Nomie K, Zhang H, Bell T, Pham L, Kadri S, et al. B-cell lymphoma patient-derived xenograft models enable drug discovery and are a platform for personalized therapy. Clin Cancer Res. 2017;23(15):4212–23.CrossRefPubMedPubMedCentral
55.
Wong NC, Bhadri VA, Maksimovic J, Parkinson-Bates M, Ng J, Craig JM, et al. Stability of gene expression and epigenetic profiles highlights the utility of patient-derived paediatric acute lymphoblastic leukaemia xenografts for investigating molecular mechanisms of drug resistance. BMC Genomics. 2014;15:416.CrossRefPubMedPubMedCentral
56.
Nahimana A, Aubry D, Breton CS, Majjigapu SR, Sordat B, Vogel P, et al. The anti-lymphoma activity of APO866, an inhibitor of nicotinamide adenine dinucleotide biosynthesis, is potentialized when used in combination with anti-CD20 antibody. Leuk Lymphoma. 2014;55(9):2141–50.CrossRefPubMed
57.
•• Zitvogel L, Pitt JM, Daillere R, Smyth MJ, Kroemer G. Mouse models in oncoimmunology. Nat Rev Cancer. 2016;16(12):759–73. This article provides comprehensive insight of mouse models in oncoimmunology as well as a more in-depth analysis of humanized mouse models. CrossRefPubMed
58.
Bernardi R, Grisendi S, Pandolfi PP. Modelling haematopoietic malignancies in the mouse and therapeutical implications. Oncogene. 2002;21(21):3445–58.CrossRefPubMed
59.
60.
Holzapfel BM, Wagner F, Thibaudeau L, Levesque JP, Hutmacher DW. Concise review: humanized models of tumor immunology in the 21st century: convergence of cancer research and tissue engineering. Stem Cells. 2015;33(6):1696–704.CrossRefPubMed
61.
Haji Y, Suzuki M, Moriya K, So T, Hozumi K, Mizuma M, et al. Activation of Notch1 promotes development of human CD8(+) single positive T cells in humanized mice. Biochem Biophys Res Commun. 2014;447(2):346–51.CrossRefPubMed
62.
Romero-Masters JC, Ohashi M, Djavadian R, Eichelberg MR, Hayes M, Bristol JA, et al. An EBNA3C-deleted Epstein-Barr virus (EBV) mutant causes B-cell lymphomas with delayed onset in a cord blood-humanized mouse model. PLoS Pathog. 2018;14(8):e1007221.CrossRefPubMedPubMedCentral
63.
Ma SD, Xu X, Jones R, Delecluse HJ, Zumwalde NA, Sharma A, et al. PD-1/CTLA-4 blockade inhibits Epstein-Barr virus-induced lymphoma growth in a cord blood humanized-mouse model. PLoS Pathog. 2016;12(5):e1005642.CrossRefPubMedPubMedCentral
64.
Ma SD, Tsai MH, Romero-Masters JC, Ranheim EA, Huebner SM, Bristol JA, et al. Latent Membrane Protein 1 (LMP1) and LMP2A Collaborate To Promote Epstein-Barr Virus-Induced B Cell Lymphomas in a Cord Blood-Humanized Mouse Model but Are Not Essential. J Virol. 2017;91(7).
65.
Cho A, Haruyama N, Kulkarni AB. Generation of transgenic mice. Curr Protoc Cell Biol. 2009;Chapter 19:Unit 19 1.
66.
Harris AW, Pinkert CA, Crawford M, Langdon WY, Brinster RL, Adams JM. The E mu-myc transgenic mouse. A model for high-incidence spontaneous lymphoma and leukemia of early B cells. J Exp Med. 1988;167(2):353–71.CrossRefPubMed
67.
Walton MI, Eve PD, Hayes A, Henley AT, Valenti MR, De Haven Brandon AK, et al. The clinical development candidate CCT245737 is an orally active CHK1 inhibitor with preclinical activity in RAS mutant NSCLC and Emicro-MYC driven B-cell lymphoma. Oncotarget. 2016;7(3):2329–42.CrossRefPubMed
68.
Berkova Z, Wang S, Sehgal L, Patel KP, Prakash O, Samaniego F. Lymphoid hyperplasia and lymphoma in KSHV K1 transgenic mice. Histol Histopathol. 2015;30(5):559–68.PubMed
69.
Katz SG, Labelle JL, Meng H, Valeriano RP, Fisher JK, Sun H, et al. Mantle cell lymphoma in cyclin D1 transgenic mice with Bim-deficient B cells. Blood. 2014;123(6):884–93.CrossRefPubMedPubMedCentral
70.
Mishra A, La Perle K, Kwiatkowski S, Sullivan LA, Sams GH, Johns J, et al. Mechanism, consequences, and therapeutic targeting of abnormal IL15 signaling in cutaneous T-cell lymphoma. Cancer Discov. 2016;6(9):986–1005.CrossRefPubMedPubMedCentral
71.
Willerslev-Olsen A, Litvinov IV, Fredholm SM, Petersen DL, Sibbesen NA, Gniadecki R, et al. IL-15 and IL-17F are differentially regulated and expressed in mycosis fungoides (MF). Cell Cycle. 2014;13(8):1306–12.CrossRefPubMedPubMedCentral
72.
Bhadury J, Nilsson LM, Muralidharan SV, Green LC, Li Z, Gesner EM, et al. BET and HDAC inhibitors induce similar genes and biological effects and synergize to kill in Myc-induced murine lymphoma. Proc Natl Acad Sci U S A. 2014;111(26):E2721–30.CrossRefPubMedPubMedCentral
73.
Kohrt HE, Thielens A, Marabelle A, Sagiv-Barfi I, Sola C, Chanuc F, et al. Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies. Blood. 2014;123(5):678–86.CrossRefPubMedPubMedCentral
74.
Natarajan A, Hackel BJ, Gambhir SS. A novel engineered anti-CD20 tracer enables early time PET imaging in a humanized transgenic mouse model of B-cell non-Hodgkins lymphoma. Clin Cancer Res. 2013;19(24):6820–9.CrossRefPubMed
75.
Pechloff K, Holch J, Ferch U, Schweneker M, Brunner K, Kremer M, et al. The fusion kinase ITK-SYK mimics a T cell receptor signal and drives oncogenesis in conditional mouse models of peripheral T cell lymphoma. J Exp Med. 2010;207(5):1031–44.CrossRefPubMedPubMedCentral
76.
Guan C, Ye C, Yang X, Gao J. A review of current large-scale mouse knockout efforts. Genesis. 2010;48(2):73–85.PubMed
77.
Hursting SD, Perkins SN, Phang JM. Calorie restriction delays spontaneous tumorigenesis in p53-knockout transgenic mice. Proc Natl Acad Sci U S A. 1994;91(15):7036–40.CrossRefPubMedPubMedCentral
78.
Han S, Jeong AL, Lee S, Park JS, Kim KD, Choi I, et al. Adiponectin deficiency suppresses lymphoma growth in mice by modulating NK cells, CD8 T cells, and myeloid-derived suppressor cells. J Immunol. 2013;190(9):4877–86.CrossRefPubMed
79.
Whitehurst CB, Li G, Montgomery SA, Montgomery ND, Su L, Pagano JS. Knockout of Epstein-Barr virus BPLF1 retards B-cell transformation and lymphoma formation in humanized mice. MBio. 2015;6(5):e01574–15.CrossRefPubMedPubMedCentral
80.
Friedel RH, Wurst W, Wefers B, Kuhn R. Generating conditional knockout mice. Methods Mol Biol. 2011;693:205–31.CrossRefPubMed
81.
Healy JA, Nugent A, Rempel RE, Moffitt AB, Davis NS, Jiang X, et al. GNA13 loss in germinal center B cells leads to impaired apoptosis and promotes lymphoma in vivo. Blood. 2016;127(22):2723–31.CrossRefPubMedPubMedCentral
82.
Liljevald M, Rehnberg M, Soderberg M, Ramnegard M, Borjesson J, Luciani D, et al. Retinoid-related orphan receptor gamma (RORgamma) adult induced knockout mice develop lymphoblastic lymphoma. Autoimmun Rev. 2016;15(11):1062–70.CrossRefPubMed
83.
Gilani U, Shaukat M, Rasheed A, Shahid M, Tasneem F, Arshad M, et al. The implication of CRISPR/Cas9 genome editing technology in combating human oncoviruses. J Med Virol. 2019;91(1):1–13.CrossRefPubMed
84.
Katigbak A, Cencic R, Robert F, Senecha P, Scuoppo C, Pelletier J. A CRISPR/Cas9 functional screen identifies rare tumor suppressors. Sci Rep. 2016;6:38968.CrossRefPubMedPubMedCentral
85.
Chen Z, Teo AE, McCarty N. ROS-induced CXCR4 signaling regulates mantle cell lymphoma (MCL) cell survival and drug resistance in the bone marrow microenvironment via autophagy. Clin Cancer Res. 2016;22(1):187–99.CrossRefPubMed
86.
Aubrey BJ, Kelly GL, Kueh AJ, Brennan MS, O'Connor L, Milla L, et al. An inducible lentiviral guide RNA platform enables the identification of tumor-essential genes and tumor-promoting mutations in vivo. Cell Rep. 2015;10(8):1422–32.CrossRefPubMed
87.
Patwardhan RS, Pal D, Checker R, Sharma D, Sandur SK. Baicalein induces cell death in murine T cell lymphoma via inhibition of thioredoxin system. Int J Biochem Cell Biol. 2017;91(Pt A):45–52.CrossRefPubMed
88.
Luanpitpong S, Chanthra N, Janan M, Poohadsuan J, Samart P. Y UP, et al. inhibition of O-GlcNAcase sensitizes apoptosis and reverses Bortezomib resistance in mantle cell lymphoma through modification of truncated bid. Mol Cancer Ther. 2018;17(2):484–96.CrossRefPubMed
89.
Chen KH, Wada M, Pinz KG, Liu H, Lin KW, Jares A, et al. Preclinical targeting of aggressive T-cell malignancies using anti-CD5 chimeric antigen receptor. Leukemia. 2017;31(10):2151–60.CrossRefPubMedPubMedCentral
90.
Pinz K, Liu H, Golightly M, Jares A, Lan F, Zieve GW, et al. Preclinical targeting of human T-cell malignancies using CD4-specific chimeric antigen receptor (CAR)-engineered T cells. Leukemia. 2016;30(3):701–7.CrossRefPubMed
91.
Giavridis T, van der Stegen SJC, Eyquem J, Hamieh M, Piersigilli A, Sadelain M. CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade. Nat Med. 2018;24(6):731–8.CrossRefPubMedPubMedCentral
92.
Norelli M, Camisa B, Barbiera G, Falcone L, Purevdorj A, Genua M, et al. Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. Nat Med. 2018;24(6):739–48.CrossRefPubMed
93.
Frey N. Cytokine release syndrome: who is at risk and how to treat. Best Pract Res Clin Haematol. 2017;30(4):336–40.CrossRefPubMed
94.
Metadaten
Titel
Development and Significance of Mouse Models in Lymphoma Research
verfasst von
Jordan N. Noble
Anjali Mishra
Publikationsdatum
08.03.2019
Verlag
Springer US
Erschienen in
Current Hematologic Malignancy Reports / Ausgabe 2/2019
Print ISSN: 1558-8211
Elektronische ISSN: 1558-822X
DOI
https://doi.org/10.1007/s11899-019-00504-0

Weitere Artikel der Ausgabe 2/2019

Current Hematologic Malignancy Reports 2/2019 Zur Ausgabe

Acute Lymphocytic Leukemias (K Ballen and M Keng, Section Editors)

Relapsed T Cell ALL: Current Approaches and New Directions

Stem Cell Transplantation (R Maziarz, Section Editor)

Autologous Haematopoietic Stem Cell Transplantation in Multiple Sclerosis: a Review of Current Literature and Future Directions for Transplant Haematologists and Oncologists

Correction

Correction to: Autologous Haematopoietic Stem Cell Transplantation in Multiple Sclerosis: a Review of Current Literature and Future Directions for Transplant Haematologists and Oncologists

Multiple Myeloma (P Kapoor, Section Editor)

Challenges and Strategies in the Management of Multiple Myeloma in the Elderly Population

Multiple Myeloma (P Kapoor, Section Editor)

Solitary Plasmacytoma: a Review of Diagnosis and Management

ReviewPaper

Recent Advances in Adult Acute Lymphoblastic Leukemia

Neu im Fachgebiet Onkologie

Alter verschlechtert Prognose bei Endometriumkarzinom

11.05.2024 Endometriumkarzinom Nachrichten

Ein höheres Alter bei der Diagnose eines Endometriumkarzinoms ist mit aggressiveren Tumorcharakteristika assoziiert, scheint aber auch unabhängig von bekannten Risikofaktoren die Prognose der Erkrankung zu verschlimmern.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Erhöhte Mortalität bei postpartalem Brustkrebs

07.05.2024 Mammakarzinom Nachrichten

Auch für Trägerinnen von BRCA-Varianten gilt: Erkranken sie fünf bis zehn Jahre nach der letzten Schwangerschaft an Brustkrebs, ist das Sterberisiko besonders hoch.

Hypertherme Chemotherapie bietet Chance auf Blasenerhalt

07.05.2024 Harnblasenkarzinom Nachrichten

Eine hypertherme intravesikale Chemotherapie mit Mitomycin kann für Patienten mit hochriskantem nicht muskelinvasivem Blasenkrebs eine Alternative zur radikalen Zystektomie darstellen. Kölner Urologen berichten über ihre Erfahrungen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise